> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cutivate Not Withdrawn Due to Safety/Efficacy: FDA
- URL: https://www.fdaweb.com/cutivate-not-withdrawn-due-to-safety-efficacy-fda/
- Published: 2021-04-01T12:00:00.000Z
- Updated: 2026-09-14T16:53:21.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5149017

*Federal Register* notice: FDA has determined that Fougera Pharmaceuticals’ Cutivate (fluticasone propionate) ointment, 0.005%, was not withdrawn from sale for safety or effectiveness reasons. The determination will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements. Cutivate is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2021-04-01/pdf/2021-06721.pdf?ref=fdaweb.com).